Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

55 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NFKB1 and NFKB2 differently modulate transcriptional profile of MT-2 cells

ABSTRACT: To investigate the effects of NFKB signaling, RNA-seq analysis was performed on both Jurkat and MT-2 cells. It was observed that either NFKB1 or NFKB2 knockout could alter the gene expression profile in MT-2 cells compared to Jurkat cells. Gene expression profiles of NFKB1/NFKB2 knockout Jurkat cells were compared to the mock edited Jurkat cells. On the other hand, it was hypothesized that the gene expression profile of MT-2 cells can be more drastically altered by NFKB1 or NFKB2 knockout. NFKB2 knockout MT-2 cells exhibited a unique gene expression profile compared to those of NFKB1 knockout MT-2 cells and mock edited MT-2 cells.

INSTRUMENT(S): Illumina NovaSeq 6000

ORGANISM(S): Homo sapiens

SUBMITTER: Yohei Sato

PROVIDER: E-MTAB-13408 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

RELA and RELC differently modulate transcriptional profile of MT-2 cells

Project description:To investigate the effects of NFKB signaling, RNA-seq analysis was performed on both Jurkat and MT-2 cells. It was observed that either RELA or RELC knockout could alter the gene expression profile in MT-2 cells compared to Jurkat cells.Gene expression profiles of RELA-C knockout Jurkat cells were compared to the mock edited Jurkat cells. On the other hand, it was hypothesized that the gene expression profile of MT-2 cells can be more drastically altered by RELA or RELC knockout compared to RELB knockout.

2024-08-01 | E-MTAB-14212 | biostudies-arrayexpress

NFKB1 and NFKB2 differently modulate transcriptional profile of MT-2 cells

Project description:NFKB1 and NFKB2 differently modulate transcriptional profile of MT-2 cells

| PRJEB67351 | ENA

AhmedMobeen2021 - NF-kB Activation Model

Project description:NF-kappaB Activation Model includes the activation of both NFKB1:RELA and NFKB2:RELB for Canonical and Non-Canonical Pathway respectively. The model includes the pathway model integrated with post-translational modifications of NF-kB subunits that regulate the NFKB1:RELA and NFKB2:RELB activity. The processes that are regulated by NF-kB pathway can be monitored through following readouts NFKB1:RELA Activity, NFKB2:RELB Activity, Degraded RelA, Degraded RelB, Degraded IkB, Degraded NIK, Apoptosis, Tumour, Antiviral Activity, B Cell Growth and Cell Migration. However, last 5 processes above are also influenced by other pathways too, therefore while making predictions, caution has to be exercised.

2022-05-27 | MODEL2001290001 | BioModels

Transcriptomes of novel human genomic safe harbor sites for gene and cell therapies

Project description:Bulk RNA-sequencing experiments were performed to analyze the transcriptomic effects of such integrations into two newly established genomic safe harbor sites. Jurkat and HEK293T cells were edited to integrate CMV-mRuby expressing cassette into Rogi2 genomic safe harbor site using Cas9 RNP

2022-02-11 | E-MTAB-11289 | biostudies-arrayexpress

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

Project description:Treatment with Menin inhibitor (MI) disrupts interaction between Menin and MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of survival of AML harboring MLL1 re-arrangement (r) and FP, or expressing mutant (mt)-NPM1. Following MI treatment, although clinical responses are common, majority of patients with AML with MLLr or mt-NPM1 succumb to their disease. Pre-clinical studies presented here demonstrate that genetic knockout or degradation of Menin, or treatment with the MI SNDX-50469 reduces MLL1/MLL1-FP targets, associated with MI-induced differentiation and loss of viability. MI treatment also attenuates BCL2 and CDK6 levels. Co-treatment with SNDX-50469 and BCL2 inhibitor (venetoclax), or CDK6 inhibitor (abemaciclib) induces synergistic lethality in cell lines and patient-derived AML cells harboring MLL1r or mtNPM1. Combined therapy with SNDX-5613 and venetoclax exerts superior in vivo efficacy in cell line or PD AML cell xenografts harboring MLL1r or mt-NPM1. Synergy with the MI-based combinations is preserved against MLLr AML cells expressing FLT3 mutation, also CRISPR edited to introduce mtTP53. These findings highlight the promise of clinically testing these MI-based combinations against AML harboring MLL1r or mtNPM1.

2022-03-12 | GSE190719 | GEO

Effect of HIV infection on co-stimulatory capacity of dendritic cells

Project description:HIV uses dendritic cells as a carrier to infect its target CD4+ T cells. At the same time, it also hampers DCs function in terms of their T cell stimulatory capacity and cytokine secretion. We have shown that HIV causes reduction in the expression of co-stimulatory molecules, CD80 and CD86 by DCs at the mRNA level irrespective of the viral subtype or the mode in DC-HIV interaction. The microarray experiments were performed to understand the changes in the transcription factor profile of HIV infected DCs which may in turn lead to reduced CD80/CD86 expression as well as the effect of HIV infection on other co-stimulatory molecules on DCs. The data suggests that TFs NFKB1, NFKB2, REL and MYB may be responsible for the observed decrease in CD80 and CD86 expression and that HIV infection also hampers the expression of other co-stimulatory molecules like CD70, CD30, 4-1BB, OX40L etc.

2011-03-15 | GSE21017 | GEO

Transcriptional regulators of the amino acid response pathway in leukemia

Project description:CRISPR/Cas9-based genetic screening revealed ZBTB1 as a critical mediator of the response of T-ALL cells to asparagine deprivation. ZBTB1 regulates the transcription of ASNS, a transcriptional target of ATF4. Loss of ZBTB1 results in decreased transcription and expression of ASNS. ChIP-Sequencing reveals that both ATF4 and ZBTB1 enrich in the promoter of ASNS. This dataset contains the RNA-Seq, ChIP-Seq and ATAC-Seq data on three different cell lines (WT Jurkat cells, ZBTB1 knockout Jurkat cells and ZBTB1 knockout Jurkat cells expressing ZBTB1 cDNA) in support of these findings.

2020-03-31 | GSE145783 | GEO

Low pass whole methylome enzymatic sequencing of 11 T-ALL cell lines untreated and after treatment with different concentrations of 5-azacytidine (AZA), 5-aza-2′-deoxycytidine (DEC) and GSK3685032 (GSK5032) for 3 and 7 days

Project description:Here we performed low coverage whole genome enzymatic-mehtyl-conversion sequencing (EM-seq) of 11 commercially available T-ALL cell lines to evaluate their global DNA methylation profile. We then proceeded to treat ALL-SIL, SUP-T1, LOUCY and JURKAT with varying concentrations (0-3000 nM) of three different hypomethylating agents, 5-azacytidine (AZA), 5-aza-2′-deoxycytidine (DEC) and GSK3685032 (GSK5032), for 3 and 7 days to evaluate their DNA demethylating ability.

2024-10-13 | E-MTAB-14197 | biostudies-arrayexpress

TNF-induced gene-expressions in Nfkb2-/- MEFs and its derivatives

Project description:As such, TNF triggers the canonical NF-?B pathway to induce a nuclear NF-?B activity composed of the RelA:p50 dimer in WT cells. Nfkb2 encodes p100, which regulates the activity of the RelB NF-?B heterodimers during immune cell-differentiation via the noncanonical pathway. Our biochemical analyses revealed that an absence of p100 instead repositions RelB under the control of the TNF-activated canonical pathway. Indeed, chronic TNF treatment of Nfkb2-/- cells activates the RelA:p50 dimer and an additional RelB:p50 dimer. On the other hand, TNF stimulation of Relb-/-Nfkb2-/- and Rela-/-Nfkb2-/- MEFs exclusively activated the RelA:p50 dimer and the RelB:p50 dimer, respectively. We treated this panel of knockout MEFs with TNF for 6h before being subjected to microarray mRNA analysis. We also included in our analysis WT MEFs and Rela-/-Relb-/-Rel-/- MEFs, which served as a negative control. Our analyses revealed overlapping and distinct gene-expression specificities of RelA:p50 and RelB:p50 dimers activated in mutant cells in response to TNF.

2019-06-13 | GSE99980 | GEO

mRNA and microRNA microarray analysis on human Jurkat T cells exposed to silver nanoparticles and silver ions

Project description:To identify genes and pathways involved in AgNPs and Ag ion toxicity, mRNA microarray analysis was conducted on human Jurkat T cells. The results indicate that more DEGs were induced by AgNPs than by Ag ion and AgNPs induced gene expression were not clustered with control and Ag ion induced ones. DEG analysis indicated that metallothionein (MT) 2A, 1H, 1F, and 1A and endonucleases G like 1 (ENDOGL1) were upregulated by AgNPs exposure more than 2 folds compared to control. Jurkat T cells were exposed to 0.2 mg/L of AgNPs and Ag ions for 24 h. After treatment, total RNA was extracted and microarray was conducted on control, AgNPs treated and Ag ion treated Jurktat T cells. Microarray analysis were performed in triplicate. Jurkat T cells were exposed to 0.2 mg/L of AgNPs and Ag ions for 24 h. After treatment, total RNA was extracted and mi RNA microarray was conducted on control, AgNPs treated and Ag ion treated Jurktat T cells.

2010-06-24 | E-GEOD-20692 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data